Xenetic Biosciences, Inc.
Index- P/E- EPS (ttm)-0.52 Insider Own8.07% Shs Outstand13.44M Perf Week-9.64%
Market Cap10.29M Forward P/E- EPS next Y-0.38 Insider Trans0.00% Shs Float12.71M Perf Month-24.35%
Income-5.90M PEG- EPS next Q-0.12 Inst Own7.30% Short Float1.54% Perf Quarter-24.63%
Sales1.40M P/S7.35 EPS this Y67.80% Inst Trans-27.57% Short Ratio0.94 Perf Half Y-55.40%
Book/sh1.26 P/B0.55 EPS next Y- ROA-33.70% Target Price4.00 Perf Year-62.59%
Cash/sh1.10 P/C0.64 EPS next 5Y- ROE-36.00% 52W Range0.45 - 5.68 Perf YTD-46.06%
Dividend- P/FCF- EPS past 5Y64.30% ROI-31.20% 52W High-87.75% Beta2.46
Dividend %- Quick Ratio15.90 Sales past 5Y-17.30% Gross Margin- 52W Low53.33% ATR0.09
Employees4 Current Ratio15.90 Sales Q/Q100.00% Oper. Margin- RSI (14)38.35 Volatility13.33% 12.62%
OptionableYes Debt/Eq0.00 EPS Q/Q23.00% Profit Margin- Rel Volume0.30 Prev Close0.70
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume207.00K Price0.70
Recom2.00 SMA20-3.69% SMA50-23.75% SMA200-53.77% Volume62,614 Change-0.63%
Jan-08-20Initiated Maxim Group Buy $2.50
May-18-22 08:15AM  
May-12-22 04:05PM  
Apr-27-22 06:30AM  
Mar-23-22 08:30AM  
Jan-12-22 10:35AM  
Nov-12-21 08:00AM  
Nov-04-21 03:01PM  
Sep-09-21 08:05AM  
Sep-08-21 08:00AM  
Aug-13-21 08:05AM  
Jul-30-21 11:30AM  
Jul-28-21 02:00PM  
Jul-27-21 08:27AM  
Jul-26-21 07:00AM  
May-12-21 07:00AM  
May-10-21 08:30AM  
Mar-29-21 08:05AM  
Mar-17-21 08:00AM  
Mar-03-21 08:05AM  
Mar-01-21 09:49AM  
Feb-16-21 07:30AM  
Feb-01-21 09:47AM  
Jan-14-21 08:00AM  
Jan-05-21 08:05AM  
Dec-14-20 11:15AM  
Dec-10-20 07:42AM  
Dec-09-20 11:35AM  
Nov-13-20 08:00AM  
Nov-05-20 08:05AM  
Sep-09-20 08:35AM  
Sep-08-20 09:34AM  
Aug-13-20 07:05AM  
Jul-30-20 08:05AM  
Jul-01-20 08:05AM  
Jun-16-20 08:05AM  
Jun-08-20 08:35AM  
May-19-20 07:35AM  
May-14-20 04:05PM  
Apr-15-20 08:35AM  
Mar-27-20 09:00AM  
Feb-27-20 08:00AM  
Feb-26-20 08:00AM  
Feb-13-20 08:00AM  
Feb-11-20 08:05AM  
Jan-14-20 08:35AM  
Nov-15-19 08:30AM  
Oct-29-19 07:05AM  
Oct-18-19 11:21AM  
Oct-16-19 08:05AM  
Oct-08-19 08:30AM  
Jul-22-19 08:00AM  
Jul-17-19 08:45AM  
Jul-05-19 01:19PM  
Jun-24-19 09:08AM  
Jun-20-19 10:24AM  
May-14-19 07:42AM  
May-13-19 08:05AM  
May-02-19 07:05AM  
Apr-01-19 07:30AM  
Mar-05-19 09:27AM  
Mar-04-19 08:00AM  
Dec-04-18 02:57PM  
Aug-14-18 11:37PM  
Jun-25-18 07:30AM  
May-25-18 03:29PM  
Feb-05-18 08:09PM  
Jan-19-18 05:35PM  
Jan-02-18 04:29PM  
Dec-08-17 01:53PM  
Nov-30-17 07:35PM  
Nov-15-17 07:05AM  
Nov-02-17 08:05AM  
Oct-31-17 09:05AM  
Oct-04-17 01:16PM  
Oct-02-17 10:45AM  
Aug-23-17 08:05AM  
Aug-15-17 08:05AM  
Aug-14-17 05:00PM  
Jul-18-17 04:05PM  
Jun-26-17 08:35AM  
May-22-17 01:05PM  
May-16-17 07:00AM  
May-09-17 08:35AM  
May-01-17 08:30AM  
Apr-20-17 07:35AM  
Apr-04-17 07:30PM  
Apr-03-17 07:35AM  
Mar-31-17 05:10PM  
Mar-29-17 10:56AM  
Mar-27-17 08:05AM  
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.